For women with early-stage breast cancer, examining the tumor’s clinical characteristics and treatment already given is more effective than genetic tests in predicting the likelihood of recurrence more than 5 years after diagnosis, according to a recent study.
The analysis evaluated how effectively 5 scoring methods predicted recurrence in nearly 10 000 postmenopausal women with early-stage breast cancer. All 5 methods performed similarly during the first 5 years of the study. However, during 5 to 10 years of follow-up, the clinical treatment score was most effective in predicting recurrence. Two genetic tests also added significantly to the clinical treatment score’s ability to predict recurrence risk.
From JAMA’s Daily News Site. JAMA. 2013;310(1):21. doi:10.1001/jama.2013.7753